William J. Link PhD - 12 Jun 2025 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role: Director
Signature: /s/ Scott Sieckert, Attorney-in-Fact
Issuer symbol: TARS
Transactions as of: 12 Jun 2025
Net transactions value: $0
Form type: 4
Filing time: 16 Jun 2025, 16:03:22 UTC
Previous filing: 04 Jun 2025
Next filing: 10 Sep 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
LINK WILLIAM J PHD	Director	C/O TARSUS PHARMACEUTICALS, INC., 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE	/s/ Scott Sieckert, Attorney-in-Fact	16 Jun 2025	0001228684

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TARS	Common Stock	Options Exercise		+3,350	+2%		170,448	13 Jun 2025	Direct	F1
holding	TARS	Common Stock						10,446	12 Jun 2025	By Link Family Enterprise, LP	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TARS	Stock Option (right to buy)	Award	$0	+4,540		$0.000000	4,540	12 Jun 2025	Common Stock	4,540	$40.95	Direct	F3
transaction	TARS	Restricted Stock Units	Award	$0	+2,954		$0.000000	2,954	12 Jun 2025	Common Stock	2,954		Direct	F4, F5
transaction	TARS	Restricted Stock Units	Options Exercise	$0	-3,350	-100%	$0.000000	0	13 Jun 2025	Common Stock	3,350		Direct	F4, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.
F2	The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the controlling member of Link Family Enterprise, LP.
F3	Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
F4	Each RSU represents a contingent right to receive one share of the Company's common stock.
F5	RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
F6	RSUs granted on June 13, 2024, in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.